Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA. Van Cutsem E, et al. Among authors: scherer sj. J Clin Oncol. 2012 Jun 10;30(17):2119-27. doi: 10.1200/JCO.2011.39.9824. Epub 2012 May 7. J Clin Oncol. 2012. PMID: 22565005 Clinical Trial.
Genetic markers of bevacizumab-induced hypertension.
Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C. Lambrechts D, et al. Among authors: scherer sj. Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21. Angiogenesis. 2014. PMID: 24558090
Markers of response for the antiangiogenic agent bevacizumab.
Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Lambrechts D, et al. Among authors: scherer sj. J Clin Oncol. 2013 Mar 20;31(9):1219-30. doi: 10.1200/JCO.2012.46.2762. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401453 Review.
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E. Lambrechts D, et al. Among authors: scherer sj. Lancet Oncol. 2012 Jul;13(7):724-33. doi: 10.1016/S1470-2045(12)70231-0. Epub 2012 May 17. Lancet Oncol. 2012. PMID: 22608783
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.
Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC. Zhou C, et al. Among authors: scherer sj. Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28. Br J Cancer. 2016. PMID: 27351218 Free PMC article. Clinical Trial.
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.
Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC. Backen A, et al. Among authors: scherer sj. Clin Cancer Res. 2014 Sep 1;20(17):4549-4558. doi: 10.1158/1078-0432.CCR-13-3248. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947924 Free PMC article. Clinical Trial.
46 results